Reason for request
Extension of indication
Clinical Benefit
| Substantial |
Substantial in the treatment of SJIA. |
Clinical Added Value
| moderate |
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. |
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
Jj55CSX8YFyfkjk6
